pBabe EGFR Del1 Citations (8)

Originally described in: Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M Cancer Biol Ther. 2007 May . 6(5):661-7. PubMed Journal

---

Articles Citing pBabe EGFR Del1

Articles
The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. Clin Cancer Res. 2015 May 11. pii: clincanres.0560.2015. PubMed
Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. Hidaka N, Iwama E, Kubo N, Harada T, Miyawaki K, Tanaka K, Okamoto I, Baba E, Akashi K, Sasaki H, Nakanishi Y. Lung Cancer. 2017 Jun;108:75-82. doi: 10.1016/j.lungcan.2017.02.019. Epub 2017 Mar 1. PubMed
A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Song X, Qi X, Wang Q, Zhu W, Li J. Am J Cancer Res. 2017 Sep 1;7(9):1884-1898. eCollection 2017. PubMed
Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients. Yu Q, Huang F, Zhang M, Ji H, Wu S, Zhao Y, Zhang C, Wu J, Wang B, Pan B, Zhang X, Guo W. Mol Med Rep. 2017 Aug;16(2):1157-1166. doi: 10.3892/mmr.2017.6712. Epub 2017 Jun 7. PubMed
Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. Shibahara D, Tanaka K, Iwama E, Kubo N, Ota K, Azuma K, Harada T, Fujita J, Nakanishi Y, Okamoto I. J Thorac Oncol. 2018 Jul;13(7):926-937. doi: 10.1016/j.jtho.2018.03.012. Epub 2018 Mar 27. PubMed
Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, Ushijima M, Furukawa Y, Sasaki Y, Otsu K, Sakyo T, Abe M, Yonezawa H, Ishibashi F, Matsuura M, Tomida A, Seimiya H, Yamori T, Iwao M, Uehara Y. Cancer Sci. 2021 May;112(5):1963-1974. doi: 10.1111/cas.14839. Epub 2021 Mar 24. PubMed
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. Tsutsumi H, Iwama E, Ibusuki R, Shimauchi A, Ota K, Yoneshima Y, Inoue H, Tanaka K, Nakanishi Y, Okamoto I. Lung Cancer. 2023 Jan;175:101-111. doi: 10.1016/j.lungcan.2022.11.018. Epub 2022 Nov 29. PubMed
Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. Pan J, Xiong D, Zhang Q, Palen K, Shoemaker RH, Johnson B, Sei S, Wang Y, You M. Front Immunol. 2023 Feb 17;14:1036563. doi: 10.3389/fimmu.2023.1036563. eCollection 2023. PubMed

If you have published an article using this material, please email us at to have your article added to this page.